These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 28088457)

  • 1. Preformulation Characterization, Stabilization, and Formulation Design for the Acrylodan-Labeled Glucose-Binding Protein SM4-AC.
    Sahni N; Chaudhuri R; Hickey JM; Manikwar P; D'Souza A; Metters A; Joshi SB; Middaugh CR; Volkin DB
    J Pharm Sci; 2017 May; 106(5):1197-1210. PubMed ID: 28088457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of acrylodan conjugation and forced oxidation on the structural integrity, conformational stability, and binding activity of a glucose binding protein SM4 used in a prototype continuous glucose monitor.
    Hickey JM; Sahni N; Chaudhuri R; D'Souza A; Metters A; Joshi SB; Russell Middaugh C; Volkin DB
    Protein Sci; 2017 Mar; 26(3):527-535. PubMed ID: 27997712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Buffers in Protein Formulations.
    Zbacnik TJ; Holcomb RE; Katayama DS; Murphy BM; Payne RW; Coccaro RC; Evans GJ; Matsuura JE; Henry CS; Manning MC
    J Pharm Sci; 2017 Mar; 106(3):713-733. PubMed ID: 27894967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of pH on the glucose response of the glucose-galactose binding protein L255C labeled with Acrylodan.
    El-Sayed MM; Brown SR; Mupparapu K; Tolosa L
    Int J Biol Macromol; 2016 May; 86():282-7. PubMed ID: 26812111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorescent responses of acrylodan-labeled plasma gelsolin.
    Reid SW; Koepf EK; Burtnick LD
    Arch Biochem Biophys; 1993 Apr; 302(1):31-6. PubMed ID: 8385903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Freeze-Drying of L-Arginine/Sucrose-Based Protein Formulations, Part 2: Optimization of Formulation Design and Freeze-Drying Process Conditions for an L-Arginine Chloride-Based Protein Formulation System.
    Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
    J Pharm Sci; 2015 Dec; 104(12):4241-4256. PubMed ID: 26422647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of sucrose hydrolysis on the stability of protein therapeutics during accelerated formulation studies.
    Banks DD; Hambly DM; Scavezze JL; Siska CC; Stackhouse NL; Gadgil HS
    J Pharm Sci; 2009 Dec; 98(12):4501-10. PubMed ID: 19388069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerating Vaccine Formulation Development Using Design of Experiment Stability Studies.
    Ahl PL; Mensch C; Hu B; Pixley H; Zhang L; Dieter L; Russell R; Smith WJ; Przysiecki C; Kosinski M; Blue JT
    J Pharm Sci; 2016 Oct; 105(10):3046-3056. PubMed ID: 27522919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a candidate stabilizing formulation for bulk storage of a double mutant heat labile toxin (dmLT) protein based adjuvant.
    Toprani VM; Sahni N; Hickey JM; Robertson GA; Middaugh CR; Joshi SB; Volkin DB
    Vaccine; 2017 Oct; 35(41):5471-5480. PubMed ID: 28551040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards development of stable formulations of a live attenuated bacterial vaccine: a preformulation study facilitated by a biophysical approach.
    Zeng Y; Fan H; Chiueh G; Pham B; Martin R; Lechuga-Ballesteros D; Truong VL; Joshi SB; Middaugh CR
    Hum Vaccin; 2009 May; 5(5):322-31. PubMed ID: 19221516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long chain lipid based tamoxifen NLC. Part I: preformulation studies, formulation development and physicochemical characterization.
    Shete H; Patravale V
    Int J Pharm; 2013 Sep; 454(1):573-83. PubMed ID: 23535345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ionic strength and pH on the physical and chemical stability of a monoclonal antibody antigen-binding fragment.
    Wang T; Kumru OS; Yi L; Wang YJ; Zhang J; Kim JH; Joshi SB; Middaugh CR; Volkin DB
    J Pharm Sci; 2013 Aug; 102(8):2520-37. PubMed ID: 23824562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability of buffer-free freeze-dried formulations: A feasibility study of a monoclonal antibody at high protein concentrations.
    Garidel P; Pevestorf B; Bahrenburg S
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):125-39. PubMed ID: 26455339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthrax vaccine powder formulations for nasal mucosal delivery.
    Jiang G; Joshi SB; Peek LJ; Brandau DT; Huang J; Ferriter MS; Woodley WD; Ford BM; Mar KD; Mikszta JA; Hwang CR; Ulrich R; Harvey NG; Middaugh CR; Sullivan VJ
    J Pharm Sci; 2006 Jan; 95(1):80-96. PubMed ID: 16315230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous production of itraconazole-based solid dispersions by hot melt extrusion: Preformulation, optimization and design space determination.
    Thiry J; Lebrun P; Vinassa C; Adam M; Netchacovitch L; Ziemons E; Hubert P; Krier F; Evrard B
    Int J Pharm; 2016 Dec; 515(1-2):114-124. PubMed ID: 27720874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preformulation study of highly purified inactivated polio vaccine, serotype 3.
    Qi W; Zeng Y; Orgel S; Francon A; Kim JH; Randolph TW; Carpenter JF; Middaugh CR
    J Pharm Sci; 2014 Jan; 103(1):140-51. PubMed ID: 24282078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High throughput formulation: strategies for rapid development of stable protein products.
    Nayar R; Manning MC
    Pharm Biotechnol; 2002; 13():177-98. PubMed ID: 11987752
    [No Abstract]   [Full Text] [Related]  

  • 18. A dynamical investigation of acrylodan-labeled mutant phosphate binding protein.
    Lundgren JS; Salins LL; Kaneva I; Daunert S
    Anal Chem; 1999 Feb; 71(3):589-95. PubMed ID: 9989379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of new ophthalmic suspension prednisolone acetate 1%.
    Akram M; Shyum SB; Gauhar S
    Pak J Pharm Sci; 2010 Apr; 23(2):149-54. PubMed ID: 20363691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical characterization and formulation development of a recombinant pneumolysoid protein-based pneumococcal vaccine.
    Hu L; Joshi SB; Liyanage MR; Pansalawatta M; Alderson MR; Tate A; Robertson G; Maisonneuve J; Volkin DB; Middaugh CR
    J Pharm Sci; 2013 Feb; 102(2):387-400. PubMed ID: 23161162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.